Holen Sie sich die Stockscreener-App
314.40
1.92%
5.92
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Is Alnylam Pharmaceuticals (ALNY) one of the best upside stocks to invest in right now? - MSN
Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? - Finviz
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback? - simplywall.st
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations (ALNY) - Seeking Alpha
RBC Capital lowers Alnylam Pharmaceuticals stock price target on short-term headwinds - Investing.com Canada
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down - TradingView
Demystifying Alnylam Pharmaceuticals: Insights From 13 Analyst Reviews - Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript - Insider Monkey
RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating - marketscreener.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $425.00 at Chardan Capital - MarketBeat
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) ROE Of 19% Impressive? - Yahoo Finance
Rhumbline Advisers Sells 3,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
RNA Therapeutics Market Set to Boom: Strategic Insights - openPR.com
Why Alnylam Pharmaceuticals Stock Slipped Today - The Globe and Mail
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Alnylam turns a profit for first time in 24-year history - The Business Journals
Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q4 2025 Earnings Conference - 富途牛牛
Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlig - GuruFocus
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion - MSN
Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Valuation Check After Swing To Profit On Strong 2025 Earnings - simplywall.st
ALNY: Needham Maintains Buy Rating with Lowered Price Target | A - GuruFocus
Needham & Company LLC Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results - MarketBeat
Earnings call transcript: Alnylam Q4 2025 beats EPS, misses revenue forecast - Investing.com Nigeria
Alnylam Pharmaceuticals (ALNY) Projects Significant Revenue Grow - GuruFocus
Earnings call transcript: Alnylam Q4 2025 beats EPS, misses revenue forecast By Investing.com - Investing.com India
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance - FinancialContent
Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings - Yahoo! Finance Canada
Alnylam Pharmaceuticals (ALNY) Q4 Earnings Miss Estimates - GuruFocus
Alnylam: Q4 Earnings Snapshot - kens5.com
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates - Yahoo Finance
Alnylam: Fourth Quarter Financial Highlights - Bitget
ALNYLAM PHARMACEUTICALS ($ALNY) Releases Q4 2025 Earnings - Quiver Quantitative
Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook - marketscreener.com
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share - marketscreener.com
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B - marketscreener.com
ALNYLAM PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress - Yahoo Finance
Krilogy Financial LLC Acquires New Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc impacted by rising ratesPortfolio Gains Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
Alnylam earnings ahead: Can blockbuster TTR drug deliver? By Investing.com - Investing.com Canada
Will Alnylam Pharmaceuticals Inc. stock return to pre crisis levels2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - mfd.ru
Envestnet Asset Management Inc. Has $54.25 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Have A Healthy Balance Sheet? - Yahoo Finance
Candriam S.C.A. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026? - TIKR.com
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Unpacking A 46.21% Potential Upside - DirectorsTalk Interviews
Do options traders know something about Alnylam Pharmaceuticals stock we don't? - MSN
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - MSN
Insider Trends: Should value investors consider Alnylam Pharmaceuticals Inc2025 AllTime Highs & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? - Finviz
Allianz Asset Management GmbH Decreases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Hantz Financial Services Inc. - MarketBeat
Alnylam Pharmaceuticals (ALNY) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 49% Undervaluation? - Yahoo Finance
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Revenue Outlook And Long Term Growth Targets - simplywall.st
Alnylam Pharmaceuticals (BIT:1ALNY) Price Target Decreased by 11.40% to 411.81 - Nasdaq
Alnylam Pharmaceuticals (ALNY): Investor Outlook with a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd - MarketBeat
0.10%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):